NCT07468071 2026-04-02
KontRASt-R
Novartis
Phase 1/2 Not yet recruiting
Clinical Trials
8 trialsNCT07432984 2026-02-25
FMT-LUNG
Samsung Medical Center
Phase 2 Not yet recruiting
NCT06977828 2025-06-29
A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06883552 2025-03-19
An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer
Sichuan University
Phase 2 Not yet recruiting
NCT06704620 2024-12-16
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Not yet recruiting
NCT06607926 2024-09-23
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
Xuanwu Hospital, Beijing
Phase NA Not yet recruiting
NCT06475755 2024-06-26
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
Tang-Du Hospital
Phase 2 Not yet recruiting
NCT05990127 2023-08-14
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
Akeso
Phase 3 Not yet recruiting